In the imatinib group , the most common grade 3-4 adverse events were hypophosphataemia ( 19 [ 6 % ] ) , anaemia ( 17 [ 5 % ] ) , abdominal pain ( 13 ; 4 % ) , and elevated lipase level ( 15 ; 5 % ) , and in the nilotinib group were anaemia ( 18 ; 6 % ) , elevated lipase level ( 15 ; 5 % ) , elevated alanine aminotransferase concentration ( 12 ; 4 % ) , and abdominal pain ( 11 ; 3 % ) .